Compare Stocks → The attacks will come for me after releasing this… (From Porter & Company) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDigital Media StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare ShareLink copied to clipboard. NASDAQ:IMPLNASDAQ:KLDOTSE:PLINASDAQ:SNSE Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIMPLImpel Pharmaceuticals$0.27$0.02▼$4.20$956K1.17682,655 shs720,000 shsKLDOKaleido Biosciences$0.00$0.00▼$0.25$6.39M-0.063,408 shs100 shsPLIProMetic Life SciencesC$13.60C$7.13▼C$590.00C$317.06MN/A8,002 shs921 shsSNSESensei Biotherapeutics$0.64-3.0%$1.11$0.51▼$1.94$16.01M0.05286,069 shs21,516 shsThe Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIMPLImpel Pharmaceuticals0.00%0.00%0.00%0.00%-96.85%KLDOKaleido Biosciences0.00%0.00%0.00%0.00%-50.00%PLIProMetic Life Sciences0.00%0.00%0.00%0.00%0.00%SNSESensei Biotherapeutics-2.99%-1.85%-57.16%-36.80%-52.37%The attacks will come for me after releasing this… (Ad)America’s “Internal Enemies” Exposed New documentary exposes a hidden election plan in Washington D.C. that, if successful, could be more financially and culturally devastating than the dot-com blowup of 2000, the 2008 financial crisis, or the COVID crash.Click here to see how you can protect yourself today. MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationIMPLImpel PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AKLDOKaleido BiosciencesN/AN/AN/AN/AN/AN/AN/AN/APLIProMetic Life SciencesN/AN/AN/AN/AN/AN/AN/AN/ASNSESensei Biotherapeutics4.0286 of 5 stars3.53.00.04.82.51.70.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIMPLImpel PharmaceuticalsN/AN/AN/AN/AKLDOKaleido BiosciencesN/AN/AN/AN/APLIProMetic Life SciencesN/AN/AN/AN/ASNSESensei Biotherapeutics3.00Buy$4.33578.89% UpsideCurrent Analyst RatingsLatest NCYT, SNSE, KLDO, IMPL, and PLI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/3/2024SNSESensei BiotherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.005/24/2024SNSESensei BiotherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $4.005/24/2024SNSESensei BiotherapeuticsStephensSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$5.00 ➝ $5.005/14/2024SNSESensei BiotherapeuticsStephensSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$5.00(Data available from 6/15/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIMPLImpel Pharmaceuticals$20.99M0.00N/AN/A($1.86) per share0.00KLDOKaleido Biosciences$1.10M0.00N/AN/AN/ANaNPLIProMetic Life SciencesC$39.91M0.00N/A3.94C$6.07 per share0.00SNSESensei BiotherapeuticsN/AN/AN/AN/A$2.60 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIMPLImpel Pharmaceuticals-$106.31M-$3.13N/AN/AN/A-353.93%N/A-127.43%N/AKLDOKaleido BiosciencesN/A-$2.24N/AN/AN/AN/AN/AN/AN/APLIProMetic Life SciencesN/A-C$63.06N/AN/AN/AN/AN/AN/AN/ASNSESensei Biotherapeutics-$34.10M-$1.21N/AN/AN/AN/A-46.67%-40.88%8/1/2024 (Estimated)Latest NCYT, SNSE, KLDO, IMPL, and PLI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/9/2024Q1 2024SNSESensei Biotherapeutics-$0.29-$0.32-$0.03-$0.32N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthIMPLImpel PharmaceuticalsN/AN/AN/AN/AN/AKLDOKaleido BiosciencesN/AN/AN/AN/AN/APLIProMetic Life SciencesN/AN/AN/AN/AN/ASNSESensei BiotherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIMPLImpel PharmaceuticalsN/A0.190.13KLDOKaleido BiosciencesN/AN/AN/APLIProMetic Life Sciences37.474.063.66SNSESensei Biotherapeutics0.0112.0712.07OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIMPLImpel Pharmaceuticals73.88%KLDOKaleido Biosciences81.56%PLIProMetic Life SciencesN/ASNSESensei Biotherapeutics10.50%Insider OwnershipCompanyInsider OwnershipIMPLImpel Pharmaceuticals6.20%KLDOKaleido Biosciences9.00%PLIProMetic Life SciencesN/ASNSESensei Biotherapeutics25.50%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableIMPLImpel Pharmaceuticals16023.90 million22.42 millionNot OptionableKLDOKaleido Biosciences7642.62 million38.79 millionNot OptionablePLIProMetic Life Sciences48723.31 millionN/ANot OptionableSNSESensei Biotherapeutics2825.08 million18.69 millionNot OptionableNCYT, SNSE, KLDO, IMPL, and PLI HeadlinesRecent News About These CompaniesJune 5, 2024 | americanbankingnews.comSensei Biotherapeutics' (SNSE) "Buy" Rating Reaffirmed at CitigroupMay 30, 2024 | globenewswire.comSensei Biotherapeutics to Participate in Jefferies Global Healthcare ConferenceMay 28, 2024 | seekingalpha.comSNSE Sensei Biotherapeutics, Inc.May 28, 2024 | bovnews.comThe performance of Sensei Biotherapeutics Inc (SNSE) Stock has improvedMay 25, 2024 | markets.businessinsider.comBuy Rating on Sensei Biotherapeutics: Innovations and Promising Clinical DevelopmentsMay 24, 2024 | msn.comSensei stock plunges 46% in wake of Phase 1 dataMay 24, 2024 | bovnews.comSensei Biotherapeutics Inc (NASDAQ:SNSE) stock is trading -25.26 percent below its 52-week highMay 24, 2024 | investorplace.comWhy Is Sensei Biotherapeutics (SNSE) Stock Down 40% Today?May 23, 2024 | globenewswire.comSensei Biotherapeutics Presents Promising Clinical Data from Phase 1 Dose Escalation Study of SNS-101May 14, 2024 | msn.comStephens & Co. Initiates Coverage of Sensei Biotherapeutics (SNSE) with Overweight RecommendationMay 13, 2024 | markets.businessinsider.comBuy Rating Justified for Sensei Biotherapeutics Amidst Strong Pipeline and Financial StabilityMay 9, 2024 | investorplace.comSNSE Stock Earnings: Sensei Biotherapeutics Misses EPS for Q1 2024May 9, 2024 | globenewswire.comSensei Biotherapeutics Reports First Quarter 2024 Financial Results and Recent Business HighlightsApril 24, 2024 | globenewswire.comSensei Biotherapeutics to Present Topline Clinical Data from the SNS-101 Phase I Dose Escalation Study at the 2024 ASCO Annual MeetingApril 9, 2024 | globenewswire.comSensei Biotherapeutics to Participate in Canaccord Genuity's Horizons in Oncology Virtual ConferenceApril 4, 2024 | uk.investing.comSensei Biotherapeutics CFO Erin Colgan to resignApril 4, 2024 | globenewswire.comSensei Biotherapeutics Announces Nature Communications Publication Describing Mechanism of Action of SNS-101 Selectively Targeting the Active Form of VISTA within the Tumor MicroenvironmentMarch 22, 2024 | globenewswire.comSensei Biotherapeutics to Participate in the 3rd Annual VISTA SymposiumMarch 6, 2024 | globenewswire.comSensei Biotherapeutics to Present New Preclinical Data at Upcoming Scientific ConferencesFebruary 29, 2024 | markets.businessinsider.comBuy Rating Affirmed for Sensei Biotherapeutics on Strong Fiscal Health and Promising Clinical TrialsNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesIntel's Secret Plan for a Double-Digit Stock Rally RevealedBy Gabriel Osorio-Mazilli | June 7, 2024View Intel's Secret Plan for a Double-Digit Stock Rally RevealedTesla Stock is Under Pressure and at Risk of a Deep ImplosionBy Thomas Hughes | June 5, 2024View Tesla Stock is Under Pressure and at Risk of a Deep ImplosionEnergy Sector Dip Presents a Compelling Buying OpportunityBy Ryan Hasson | May 29, 2024View Energy Sector Dip Presents a Compelling Buying OpportunityCan CAVA, Red Robin, and Cracker Barrel Match Chipotle's Q1 Win?By Jeffrey Neal Johnson | May 28, 2024View Can CAVA, Red Robin, and Cracker Barrel Match Chipotle's Q1 Win?ChargePoint Can Optimize Operations with AI and ML ImplementationBy Jea Yu | June 4, 2024View ChargePoint Can Optimize Operations with AI and ML ImplementationCompany DescriptionsImpel PharmaceuticalsNASDAQ:IMPLImpel Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is Trudhesa, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine. Impel Pharmaceuticals Inc. was formerly known as Impel NeuroPharma, Inc. and changed its name to Impel Pharmaceuticals Inc. in April 2022. The company was incorporated in 2008 and is headquartered in Seattle, Washington.Kaleido BiosciencesNASDAQ:KLDOKaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease. It also develops programs for the treatment of multi drug resistant infection, chronic kidney disease, atherosclerotic cardiovascular disease, cardio-metabolic syndrome, immuno-oncology, and inflammatory bowel diseases. The company has collaboration agreements with Institute Gustave Roussy, Washington University, and Janssen. Kaleido Biosciences, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.ProMetic Life SciencesTSE:PLIPrometic Life Sciences Inc. operates as a biopharmaceutical company with two drug discovery platforms that focuses on unmet medical needs in the field of fibrosis and orphan diseases. Its product pipeline includes PBI-4050, an orally active lead drug candidate for fibrosis; plasminogen, a biopharmaceutical for the treatment of congenital plasminogen deficiency; and intravenous immunoglobulin, a preparation of antibodies purified from plasma donations from healthy individuals. The company was founded in 1992 and is based in Laval, Canada.Sensei BiotherapeuticsNASDAQ:SNSESensei Biotherapeutics, Inc., an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. It also offers SNS-101, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-103 and SNS-102, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28. It has a collaboration with The University of Washington to conduct preclinical studies for its SNS-101 program. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.